EXTENDED-RELEASE OXYCODONE HYDROCHLORIDE (OXYCONTIN®) FOR PAIN MANAGEMENT IN PATIENTS UNDERGOING ARTHROPLASTY- A COST ANALYSIS FROM THE BRAZILIAN PUBLIC AND PRIVATE HEALTHCARE SYSTEMS PERSPECTIVES
Author(s)
Demange M1, Saggia M2, Naves A3, Haas L4, Fernandes RA4
1Faculdade de Medicina da Universidade de São Paulo., São Paulo, Brazil, 2Asigma, Sao Paulo, Brazil, 3Mundipharma, São Paulo, Brazil, 4Sense Company, Rio de Janeiro, Brazil
OBJECTIVES: Pain after arthroplasty is a common condition which can result in loss of quality of life and significant financial burden. This study aims to evaluate extended-release oxycodone versus morphine in an "if necessary" regime in the management of pain post-arthroplasty, from the Brazilian public and private healthcare systems perspectives. METHODS: A decision model was developed to analyze two scenarios. In both, patients in group 1 received extended-release oxycodone and immediate-release opioid. Regarding group 2, in scenario 1, patients received immediate-release opioid and, in scenario 2, immediate-release opioid and placebo. Efficacy data were obtained from Beer et al
Conference/Value in Health Info
2015-11, ISPOR Europe 2015, Milan, Italy
Value in Health, Vol. 18, No. 7 (November 2015)
Code
PMS36
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Musculoskeletal Disorders, Systemic Disorders/Conditions